Review



human monocytic leukemia cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC human monocytic leukemia cell line
    Human Monocytic Leukemia Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 19817 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/pmc13126472-368-12-25?v=ATCC
    Average 99 stars, based on 19817 article reviews
    human monocytic leukemia cell line - by Bioz Stars, 2026-07
    99/100 stars

    Images



    Similar Products

    99
    ATCC human monocytic leukemia cell line
    Human Monocytic Leukemia Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/pmc13126472-368-12-25?v=ATCC
    Average 99 stars, based on 1 article reviews
    human monocytic leukemia cell line - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    95
    CLS Cell Lines Service GmbH human leukemia cell line thp 1
    Human Leukemia Cell Line Thp 1, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/bio_rxiv__64898__2026__06__01__729453-324-46-51?v=CLS+Cell+Lines+Service+GmbH
    Average 95 stars, based on 1 article reviews
    human leukemia cell line thp 1 - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    86
    Human Protein Atlas aldh3a2 expression in human leukemia cell lines and peripheral blood mononuclear cells
    Expression of <t>ALDH3A2</t> in healthy people and patients with AML (A) The expression of ALDH3A2 in various tumors compared with normal tissues. Data are represented as mean ± SEM. (B) Expression of ALDH3A2 in 88 leukemia cell lines. (C) The survival curve of patients with high and low expression of ALDH3A2 (n [low expression] = 121, n [high expression] = 30). (D) The expression of protein ALDH3A2 in <t>HL-60,</t> HL-60/ADM, K562, K562/ADM, and bone marrow in patients. (E) The expression of ALDH3A2 RNA in bone marrow mononuclear cells of AML patients in the CR ( n = 9), C1NR ( n = 8), and R/R ( n = 10) group. Data are represented as mean ± SEM. (F) The expression of ALDH3A2 in bone marrow mononuclear cells of 3 AML patients at their initial and recurrent stage. (G) High/low expression of ALDH3A2 and molecular mutation distribution of 66 AML patients. Data are represented as mean ± SEM. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.
    Aldh3a2 Expression In Human Leukemia Cell Lines And Peripheral Blood Mononuclear Cells, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/pmc13254865-35-0-13?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    aldh3a2 expression in human leukemia cell lines and peripheral blood mononuclear cells - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    86
    Procell Inc human myeloid leukemia cell line thp 1
    Expression of <t>ALDH3A2</t> in healthy people and patients with AML (A) The expression of ALDH3A2 in various tumors compared with normal tissues. Data are represented as mean ± SEM. (B) Expression of ALDH3A2 in 88 leukemia cell lines. (C) The survival curve of patients with high and low expression of ALDH3A2 (n [low expression] = 121, n [high expression] = 30). (D) The expression of protein ALDH3A2 in <t>HL-60,</t> HL-60/ADM, K562, K562/ADM, and bone marrow in patients. (E) The expression of ALDH3A2 RNA in bone marrow mononuclear cells of AML patients in the CR ( n = 9), C1NR ( n = 8), and R/R ( n = 10) group. Data are represented as mean ± SEM. (F) The expression of ALDH3A2 in bone marrow mononuclear cells of 3 AML patients at their initial and recurrent stage. (G) High/low expression of ALDH3A2 and molecular mutation distribution of 66 AML patients. Data are represented as mean ± SEM. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.
    Human Myeloid Leukemia Cell Line Thp 1, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/pm42107066-368-8-18?v=Procell+Inc
    Average 86 stars, based on 1 article reviews
    human myeloid leukemia cell line thp 1 - by Bioz Stars, 2026-07
    86/100 stars
      Buy from Supplier

    99
    ATCC k562 human myeloid leukemia cell line
    a, Bar plots of relative median fluorescence intensity (MFI) of granzyme B and perforin from intracellular cytokine staining of primary untreated MDS CD8 T cells after exposure to increasing doses of TGFβ. Relative MFI values are shown as mean ± SD. Data from n=6 MDS patients. Mann-Whitney U test used for statistical analysis (*p<0.05, **p<0.01). b, Top, volcano plot of differentially expressed genes in CD8 memory T cells close to (≤20µm) versus far from (>50µm) megakaryocytes. Bottom, schematic of CD8 memory T cells based on their distance to nearest megakaryocytes from spatial data. c, Relative percent spliced in (dPSI) value of differential 3’ splice site in mRNAs from SF3B1 mutant MDS patient bulk RNA-seq versus SF3B1 wild-type MDS. Highlighted names indicate mRNAs encoding proteins involved in TGFβ signaling. d, Diagram of proteins (in green) involved in TGFβ signaling which undergo aberrant RNA splicing in SF3B1 mutant MDS. e, Protein diagram of TGFBR1 with red indicating insertion of four amino acids (GPFS) encoded by the long mRNA isoform promoted in SF3B1 mutant cells. f, Alpha fold model of mutant TGFBR1 (green) overlaid with published crystal structure of wild-type TGFBR1 (gray). The GPFS amino acid insertion seen in SF3B1 mutant cells is indicated in red in the inset. g, Percentage (%) of phospho-SMAD2 Serine 465/467 (pS465/467) in <t>K562</t> cells with the indicated genetic alterations in SF3B1 or TGFBR1. Mean ± SD. Two-way ANOVA. ***p<0.001, ****p<0.0001. h , Representative flow cytometry histograms of p-SMAD2 S465/467 from (g). i, Schematic of an SF3B1-mutant megakaryocyte with increased TGFβ production suppressing cytotoxic activity of nearby CD8 + T cells (cell-extrinsic effect); mutant cell simultaneously exhibits impaired TGFβ sensing (cell-intrinsic effect).
    K562 Human Myeloid Leukemia Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/bio_rxiv__64898__2026__05__05__720208-384-1-10?v=ATCC
    Average 99 stars, based on 1 article reviews
    k562 human myeloid leukemia cell line - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC human leukemia cell lines k562
    The Effect of lovastatin on the activity, cell cycle, and apoptosis in AML cell lines <t>K562</t> and THP-1 in vitro. ( A and B ) Effects of lovastatin and 4-PBA at different concentrations on cell activities of THP-1 and K562; ( C ) Effects of lovastatin and 4-PBA on cell cycles of THP-1 and K562; ( D ) Effects of lovastatin and 4-PBA on cell apoptosis of THP-1 and K562. AML, acute myeloid leukemia. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 hours; **** p <0.0001.
    Human Leukemia Cell Lines K562, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/pmc13135768-89-1-6?v=ATCC
    Average 99 stars, based on 1 article reviews
    human leukemia cell lines k562 - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC cell culture human t cell acute lymphoblastic leukemia cell line
    The Effect of lovastatin on the activity, cell cycle, and apoptosis in AML cell lines <t>K562</t> and THP-1 in vitro. ( A and B ) Effects of lovastatin and 4-PBA at different concentrations on cell activities of THP-1 and K562; ( C ) Effects of lovastatin and 4-PBA on cell cycles of THP-1 and K562; ( D ) Effects of lovastatin and 4-PBA on cell apoptosis of THP-1 and K562. AML, acute myeloid leukemia. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 hours; **** p <0.0001.
    Cell Culture Human T Cell Acute Lymphoblastic Leukemia Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/us12606561-153-0-9?v=ATCC
    Average 99 stars, based on 1 article reviews
    cell culture human t cell acute lymphoblastic leukemia cell line - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC human promyelocytic leukemia cell line
    The Effect of lovastatin on the activity, cell cycle, and apoptosis in AML cell lines <t>K562</t> and THP-1 in vitro. ( A and B ) Effects of lovastatin and 4-PBA at different concentrations on cell activities of THP-1 and K562; ( C ) Effects of lovastatin and 4-PBA on cell cycles of THP-1 and K562; ( D ) Effects of lovastatin and 4-PBA on cell apoptosis of THP-1 and K562. AML, acute myeloid leukemia. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 hours; **** p <0.0001.
    Human Promyelocytic Leukemia Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/us12605429-1035-0-6?v=ATCC
    Average 99 stars, based on 1 article reviews
    human promyelocytic leukemia cell line - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    99
    ATCC human leukemia cell line thp 1
    The Effect of lovastatin on the activity, cell cycle, and apoptosis in AML cell lines <t>K562</t> and THP-1 in vitro. ( A and B ) Effects of lovastatin and 4-PBA at different concentrations on cell activities of THP-1 and K562; ( C ) Effects of lovastatin and 4-PBA on cell cycles of THP-1 and K562; ( D ) Effects of lovastatin and 4-PBA on cell apoptosis of THP-1 and K562. AML, acute myeloid leukemia. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 hours; **** p <0.0001.
    Human Leukemia Cell Line Thp 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+leukemia+cell+lines/10__3390_slash_molecules31081313-280-3-8?v=ATCC
    Average 99 stars, based on 1 article reviews
    human leukemia cell line thp 1 - by Bioz Stars, 2026-07
    99/100 stars
      Buy from Supplier

    Image Search Results


    Expression of ALDH3A2 in healthy people and patients with AML (A) The expression of ALDH3A2 in various tumors compared with normal tissues. Data are represented as mean ± SEM. (B) Expression of ALDH3A2 in 88 leukemia cell lines. (C) The survival curve of patients with high and low expression of ALDH3A2 (n [low expression] = 121, n [high expression] = 30). (D) The expression of protein ALDH3A2 in HL-60, HL-60/ADM, K562, K562/ADM, and bone marrow in patients. (E) The expression of ALDH3A2 RNA in bone marrow mononuclear cells of AML patients in the CR ( n = 9), C1NR ( n = 8), and R/R ( n = 10) group. Data are represented as mean ± SEM. (F) The expression of ALDH3A2 in bone marrow mononuclear cells of 3 AML patients at their initial and recurrent stage. (G) High/low expression of ALDH3A2 and molecular mutation distribution of 66 AML patients. Data are represented as mean ± SEM. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Journal: iScience

    Article Title: ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance

    doi: 10.1016/j.isci.2026.116202

    Figure Lengend Snippet: Expression of ALDH3A2 in healthy people and patients with AML (A) The expression of ALDH3A2 in various tumors compared with normal tissues. Data are represented as mean ± SEM. (B) Expression of ALDH3A2 in 88 leukemia cell lines. (C) The survival curve of patients with high and low expression of ALDH3A2 (n [low expression] = 121, n [high expression] = 30). (D) The expression of protein ALDH3A2 in HL-60, HL-60/ADM, K562, K562/ADM, and bone marrow in patients. (E) The expression of ALDH3A2 RNA in bone marrow mononuclear cells of AML patients in the CR ( n = 9), C1NR ( n = 8), and R/R ( n = 10) group. Data are represented as mean ± SEM. (F) The expression of ALDH3A2 in bone marrow mononuclear cells of 3 AML patients at their initial and recurrent stage. (G) High/low expression of ALDH3A2 and molecular mutation distribution of 66 AML patients. Data are represented as mean ± SEM. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Article Snippet: ALDH3A2 expression in human leukemia cell lines and peripheral blood mononuclear cells , Human Protein Atlas website ( https://www.proteinatlas.org/ ) , .

    Techniques: Expressing, Mutagenesis, Two Tailed Test, Comparison

    ALDH3A2-V protects AML cells from ferroptosis and cytotoxicity induced by doxorubicin (A) ALDH3A2 mRNA relative expression in HL-60/ADM and K562/ADM cells after transfection of siRNA by electroporation. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (B) The lipid peroxidation degree of HL60ADM and K562ADM cells in the control (ctrl) and ALDH3A2 knockdown (KD) groups after the same dose of doxorubicin treatment for 48 h. (C) The content of ALDH3A2 protein in HL-60, K562, U937, and KG-1α in the ALDH3A2 overexpressing (OE) group and the control (CON) group. (D) The location of ALDH3A2-V overexpression. This representative image was selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. (E) Lipid peroxidation in HL-60, K562, U937, and KG-1α in the ALDH3A2 OE group and the CON group under the same concentration of doxorubicin treatment. (F and G) Cell viability and its fitting curve of HL-60, K562, U937, and KG-1α in the ALDH3A2 OE group and the CON group under the gradient concentration of doxorubicin treatment. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Journal: iScience

    Article Title: ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance

    doi: 10.1016/j.isci.2026.116202

    Figure Lengend Snippet: ALDH3A2-V protects AML cells from ferroptosis and cytotoxicity induced by doxorubicin (A) ALDH3A2 mRNA relative expression in HL-60/ADM and K562/ADM cells after transfection of siRNA by electroporation. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (B) The lipid peroxidation degree of HL60ADM and K562ADM cells in the control (ctrl) and ALDH3A2 knockdown (KD) groups after the same dose of doxorubicin treatment for 48 h. (C) The content of ALDH3A2 protein in HL-60, K562, U937, and KG-1α in the ALDH3A2 overexpressing (OE) group and the control (CON) group. (D) The location of ALDH3A2-V overexpression. This representative image was selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. (E) Lipid peroxidation in HL-60, K562, U937, and KG-1α in the ALDH3A2 OE group and the CON group under the same concentration of doxorubicin treatment. (F and G) Cell viability and its fitting curve of HL-60, K562, U937, and KG-1α in the ALDH3A2 OE group and the CON group under the gradient concentration of doxorubicin treatment. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Article Snippet: ALDH3A2 expression in human leukemia cell lines and peripheral blood mononuclear cells , Human Protein Atlas website ( https://www.proteinatlas.org/ ) , .

    Techniques: Expressing, Transfection, Electroporation, Control, Knockdown, Over Expression, Concentration Assay, Two Tailed Test, Comparison

    ALDH3A2 affects the sensitivity of AML cells to doxorubicin by altering 4-HNE and fatty acid content (A) The content of 4-HNE in cell lysate and culture supernatant of AML cells in the doxorubicin treatment (ADR) group and control (CON) group. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (B) The content of 4-HNE in HL-60, U937, and KG-1α of the overexpressing ALDH3A2 (OE) group and the CON group under the same concentration of doxorubicin treatment. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (C) OPLS-DA was performed on the measured fatty acids. Quantitative data for fatty acid and cell viability were collected from 3 independent experiments. (D) Variable Importance in Projection(VIP) value of different fatty acids; the difference is considered significant when the VIP>1. (E) Content of three different fatty acids in the CON and OE ALDH3A2 group. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (F) Cell viability of AML cells in heptadecanoic acid, oleic acid, and linoleic acid-pretreated groups and the CON group after the treatment of doxorubicin. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (G) Lipid peroxidation in AML cells in heptadecanoic acid-, oleic acid-, and linoleic acid-pretreated groups and the CON group after the treatment of doxorubicin. These images were selected from 3 independent replicates. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, ∗∗ indicates p < 0.01 between the two groups, and ∗∗∗ indicates p < 0.001 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Journal: iScience

    Article Title: ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance

    doi: 10.1016/j.isci.2026.116202

    Figure Lengend Snippet: ALDH3A2 affects the sensitivity of AML cells to doxorubicin by altering 4-HNE and fatty acid content (A) The content of 4-HNE in cell lysate and culture supernatant of AML cells in the doxorubicin treatment (ADR) group and control (CON) group. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (B) The content of 4-HNE in HL-60, U937, and KG-1α of the overexpressing ALDH3A2 (OE) group and the CON group under the same concentration of doxorubicin treatment. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (C) OPLS-DA was performed on the measured fatty acids. Quantitative data for fatty acid and cell viability were collected from 3 independent experiments. (D) Variable Importance in Projection(VIP) value of different fatty acids; the difference is considered significant when the VIP>1. (E) Content of three different fatty acids in the CON and OE ALDH3A2 group. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (F) Cell viability of AML cells in heptadecanoic acid, oleic acid, and linoleic acid-pretreated groups and the CON group after the treatment of doxorubicin. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (G) Lipid peroxidation in AML cells in heptadecanoic acid-, oleic acid-, and linoleic acid-pretreated groups and the CON group after the treatment of doxorubicin. These images were selected from 3 independent replicates. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, ∗∗ indicates p < 0.01 between the two groups, and ∗∗∗ indicates p < 0.001 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Article Snippet: ALDH3A2 expression in human leukemia cell lines and peripheral blood mononuclear cells , Human Protein Atlas website ( https://www.proteinatlas.org/ ) , .

    Techniques: Control, Concentration Assay, Two Tailed Test, Comparison

    Effects of fatty acids and ALDH3A2 on plasma membrane fluidity and drug uptake (A) Laurdan staining showed different ratios of order and disorder phases in the control, heptadecanoic acid-, oleic acid-, or linoleic acid-treated groups. These representative images were selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. (B) Flow cytometry was employed to quantify Cy5 fluorescence intensity in control, heptadecanoic acid-, oleic acid-, or linoleic acid-pretreated groups at 2- and 4-h intervals following doxorubicin exposure. The representative image was selected from 3 independent replicate experiments. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (C) Laurdan staining showed different ratios of order and disorder phases in the control and ALDH3A2 high groups. The mCherry fluorescent protein was co-expressed with ALDH3A2, which indicates successful transfection of the overexpression plasmid into the cells. These representative images were selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. (D) U937 cells in the control group and ALDH3A2 high group were treated with Cy5-labeled doxorubicin. The mCherry fluorescent protein was co-expressed with ALDH3A2, which indicates successful transfection of the overexpression plasmid into the cells. These representative images were selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Journal: iScience

    Article Title: ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance

    doi: 10.1016/j.isci.2026.116202

    Figure Lengend Snippet: Effects of fatty acids and ALDH3A2 on plasma membrane fluidity and drug uptake (A) Laurdan staining showed different ratios of order and disorder phases in the control, heptadecanoic acid-, oleic acid-, or linoleic acid-treated groups. These representative images were selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. (B) Flow cytometry was employed to quantify Cy5 fluorescence intensity in control, heptadecanoic acid-, oleic acid-, or linoleic acid-pretreated groups at 2- and 4-h intervals following doxorubicin exposure. The representative image was selected from 3 independent replicate experiments. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (C) Laurdan staining showed different ratios of order and disorder phases in the control and ALDH3A2 high groups. The mCherry fluorescent protein was co-expressed with ALDH3A2, which indicates successful transfection of the overexpression plasmid into the cells. These representative images were selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. (D) U937 cells in the control group and ALDH3A2 high group were treated with Cy5-labeled doxorubicin. The mCherry fluorescent protein was co-expressed with ALDH3A2, which indicates successful transfection of the overexpression plasmid into the cells. These representative images were selected from 3 independent replicate experiments, with 4 fields of view evaluated per replicate. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Article Snippet: ALDH3A2 expression in human leukemia cell lines and peripheral blood mononuclear cells , Human Protein Atlas website ( https://www.proteinatlas.org/ ) , .

    Techniques: Clinical Proteomics, Membrane, Staining, Control, Flow Cytometry, Fluorescence, Transfection, Over Expression, Plasmid Preparation, Labeling, Two Tailed Test, Comparison

    In in vivo experiments, AML with high expression of ALDH3A2 exhibits a poorer response to doxorubicin (A) Schematic diagram of the process for establishing the AML mouse model. (B) In vivo bioimaging shows the success of the model and the leukemia burden in mice before and after treatment. (C) Statistics of fluorescence values ( n = 5) on days 3 and 7 of the experiment. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (D) Survival curves of mice in different groups. (E) 4-HNE content in plasma of mice in different groups ( n = 5) on day 7. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (F) 4-HNE content in plasma of AML patients with low ( n = 5) and high ( n = 5) ALDH3A2 expression levels before and after receiving chemotherapy. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired or paired two-tailed Student’s t tests for the comparison of two groups.

    Journal: iScience

    Article Title: ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance

    doi: 10.1016/j.isci.2026.116202

    Figure Lengend Snippet: In in vivo experiments, AML with high expression of ALDH3A2 exhibits a poorer response to doxorubicin (A) Schematic diagram of the process for establishing the AML mouse model. (B) In vivo bioimaging shows the success of the model and the leukemia burden in mice before and after treatment. (C) Statistics of fluorescence values ( n = 5) on days 3 and 7 of the experiment. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (D) Survival curves of mice in different groups. (E) 4-HNE content in plasma of mice in different groups ( n = 5) on day 7. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (F) 4-HNE content in plasma of AML patients with low ( n = 5) and high ( n = 5) ALDH3A2 expression levels before and after receiving chemotherapy. Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired or paired two-tailed Student’s t tests for the comparison of two groups.

    Article Snippet: ALDH3A2 expression in human leukemia cell lines and peripheral blood mononuclear cells , Human Protein Atlas website ( https://www.proteinatlas.org/ ) , .

    Techniques: In Vivo, Expressing, Fluorescence, Clinical Proteomics, Two Tailed Test, Comparison

    X24003 inhibits ALDH3A2 and enhances the cytotoxic effects of doxorubicin on resistant AML cells (A) OPLS-DA was performed on the measured fatty acid containment in the X24003 treatment group and control group. Quantitative data for fatty acid and cell viability were collected from 3 independent experiments. VIP value of different fatty acids; the difference is considered significant when the VIP>1. (B) X24003 exhibits a synergistic effect with doxorubicin in the elimination of doxorubicin-resistant AML cell lines HL-60ADM and K562ADM. (C) X24003 augments doxorubicin-induced lipid peroxidation in doxorubicin-resistant AML cell strains without affecting the parental cell lines. The representative image was selected from three independent replicate experiments. (D) In vivo bioimaging shows the success of the model and the leukemia burden in mice before and after treatment.

    Journal: iScience

    Article Title: ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance

    doi: 10.1016/j.isci.2026.116202

    Figure Lengend Snippet: X24003 inhibits ALDH3A2 and enhances the cytotoxic effects of doxorubicin on resistant AML cells (A) OPLS-DA was performed on the measured fatty acid containment in the X24003 treatment group and control group. Quantitative data for fatty acid and cell viability were collected from 3 independent experiments. VIP value of different fatty acids; the difference is considered significant when the VIP>1. (B) X24003 exhibits a synergistic effect with doxorubicin in the elimination of doxorubicin-resistant AML cell lines HL-60ADM and K562ADM. (C) X24003 augments doxorubicin-induced lipid peroxidation in doxorubicin-resistant AML cell strains without affecting the parental cell lines. The representative image was selected from three independent replicate experiments. (D) In vivo bioimaging shows the success of the model and the leukemia burden in mice before and after treatment.

    Article Snippet: ALDH3A2 expression in human leukemia cell lines and peripheral blood mononuclear cells , Human Protein Atlas website ( https://www.proteinatlas.org/ ) , .

    Techniques: Control, In Vivo

    HDAC2 binds to the promoter of the ALDH3A2 gene and regulates its expression (A) CUT&RUN indicates that HDAC2 binds to the promoter of the ALDH3A2 gene; the binding affinity is observed to decrease after treatment with chidamide. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (B) The expression of ALDH3A2 protein in AML cells following treatment with doxorubicin or chidamide. (C) Treatment of chidamide enhances lipid peroxidation induced by doxorubicin in AML cells. The representative image was selected from three independent replicate experiments. (D) Chidamide exhibits a synergistic effect with doxorubicin in the elimination of AML cells. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Journal: iScience

    Article Title: ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance

    doi: 10.1016/j.isci.2026.116202

    Figure Lengend Snippet: HDAC2 binds to the promoter of the ALDH3A2 gene and regulates its expression (A) CUT&RUN indicates that HDAC2 binds to the promoter of the ALDH3A2 gene; the binding affinity is observed to decrease after treatment with chidamide. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . (B) The expression of ALDH3A2 protein in AML cells following treatment with doxorubicin or chidamide. (C) Treatment of chidamide enhances lipid peroxidation induced by doxorubicin in AML cells. The representative image was selected from three independent replicate experiments. (D) Chidamide exhibits a synergistic effect with doxorubicin in the elimination of AML cells. Data are represented as mean ± SEM. The specific data are shown in the supplemental table . Ns indicates no statistical difference between the two groups, ∗ indicates p < 0.05 between the two groups, and ∗∗ indicates p < 0.01 between the two groups. Statistical significance was determined using unpaired two-tailed Student’s t tests for the comparison of two groups.

    Article Snippet: ALDH3A2 expression in human leukemia cell lines and peripheral blood mononuclear cells , Human Protein Atlas website ( https://www.proteinatlas.org/ ) , .

    Techniques: Expressing, Binding Assay, Two Tailed Test, Comparison

    a, Bar plots of relative median fluorescence intensity (MFI) of granzyme B and perforin from intracellular cytokine staining of primary untreated MDS CD8 T cells after exposure to increasing doses of TGFβ. Relative MFI values are shown as mean ± SD. Data from n=6 MDS patients. Mann-Whitney U test used for statistical analysis (*p<0.05, **p<0.01). b, Top, volcano plot of differentially expressed genes in CD8 memory T cells close to (≤20µm) versus far from (>50µm) megakaryocytes. Bottom, schematic of CD8 memory T cells based on their distance to nearest megakaryocytes from spatial data. c, Relative percent spliced in (dPSI) value of differential 3’ splice site in mRNAs from SF3B1 mutant MDS patient bulk RNA-seq versus SF3B1 wild-type MDS. Highlighted names indicate mRNAs encoding proteins involved in TGFβ signaling. d, Diagram of proteins (in green) involved in TGFβ signaling which undergo aberrant RNA splicing in SF3B1 mutant MDS. e, Protein diagram of TGFBR1 with red indicating insertion of four amino acids (GPFS) encoded by the long mRNA isoform promoted in SF3B1 mutant cells. f, Alpha fold model of mutant TGFBR1 (green) overlaid with published crystal structure of wild-type TGFBR1 (gray). The GPFS amino acid insertion seen in SF3B1 mutant cells is indicated in red in the inset. g, Percentage (%) of phospho-SMAD2 Serine 465/467 (pS465/467) in K562 cells with the indicated genetic alterations in SF3B1 or TGFBR1. Mean ± SD. Two-way ANOVA. ***p<0.001, ****p<0.0001. h , Representative flow cytometry histograms of p-SMAD2 S465/467 from (g). i, Schematic of an SF3B1-mutant megakaryocyte with increased TGFβ production suppressing cytotoxic activity of nearby CD8 + T cells (cell-extrinsic effect); mutant cell simultaneously exhibits impaired TGFβ sensing (cell-intrinsic effect).

    Journal: bioRxiv

    Article Title: Ecological determinants of disease and immunity in myelodysplastic syndromes

    doi: 10.64898/2026.05.05.720208

    Figure Lengend Snippet: a, Bar plots of relative median fluorescence intensity (MFI) of granzyme B and perforin from intracellular cytokine staining of primary untreated MDS CD8 T cells after exposure to increasing doses of TGFβ. Relative MFI values are shown as mean ± SD. Data from n=6 MDS patients. Mann-Whitney U test used for statistical analysis (*p<0.05, **p<0.01). b, Top, volcano plot of differentially expressed genes in CD8 memory T cells close to (≤20µm) versus far from (>50µm) megakaryocytes. Bottom, schematic of CD8 memory T cells based on their distance to nearest megakaryocytes from spatial data. c, Relative percent spliced in (dPSI) value of differential 3’ splice site in mRNAs from SF3B1 mutant MDS patient bulk RNA-seq versus SF3B1 wild-type MDS. Highlighted names indicate mRNAs encoding proteins involved in TGFβ signaling. d, Diagram of proteins (in green) involved in TGFβ signaling which undergo aberrant RNA splicing in SF3B1 mutant MDS. e, Protein diagram of TGFBR1 with red indicating insertion of four amino acids (GPFS) encoded by the long mRNA isoform promoted in SF3B1 mutant cells. f, Alpha fold model of mutant TGFBR1 (green) overlaid with published crystal structure of wild-type TGFBR1 (gray). The GPFS amino acid insertion seen in SF3B1 mutant cells is indicated in red in the inset. g, Percentage (%) of phospho-SMAD2 Serine 465/467 (pS465/467) in K562 cells with the indicated genetic alterations in SF3B1 or TGFBR1. Mean ± SD. Two-way ANOVA. ***p<0.001, ****p<0.0001. h , Representative flow cytometry histograms of p-SMAD2 S465/467 from (g). i, Schematic of an SF3B1-mutant megakaryocyte with increased TGFβ production suppressing cytotoxic activity of nearby CD8 + T cells (cell-extrinsic effect); mutant cell simultaneously exhibits impaired TGFβ sensing (cell-intrinsic effect).

    Article Snippet: The K562 human myeloid leukemia cell line was purchased from American Type Culture Collection (ATCC; #CCL-243).

    Techniques: Fluorescence, Staining, MANN-WHITNEY, Mutagenesis, RNA Sequencing, Flow Cytometry, Activity Assay

    (a) Sashimi plots of bulk RNA-sequencing data of an aberrant 3’ splice site usage in TGFBR1, MAP3K7 and SMURF2 mRNA in SF3B1 mutant acute myeloid leukemia (AML) (top; n=76 patients), SF3B1 wild-type (WT) AML (middle; n=739 patients), and normal bone marrow (bottom; n=26 patients). Red lines indicate SF3B1 mutant-specific junctions while black lines represent junction spanning reads in wild-type cells. The number of reads is listed, and the frequency of reads is in parentheses. b , Crystal structure of the short-isoform of TGFBR1 (grey) overlaid with that of the alpha-fold predicted model of SF3B1 mutant induced long-isoform (green). c, RT-PCR analysis of aberrant 3’ splice events in TGFBR1, MAP3K7, and SMURF2 in human isogenic K562 cells with knockin of SF3B1 K700E mutation. d , RT-PCR analysis of endogenous TGFBR1 , MAP3K7, and SMURF2 splicing in primary samples in healthy bone marrow control patients (n=5), patients with SF3B1 K700E mutant MDS (n=5) and non-splicing factor mutant patients with MDS (n=5). e , Sanger sequencing electropherogram of the top and bottom PCR products from gel-purified TGFBR1 RT-PCRs from MDS SF3B1 mutant patients shown in ( c ). The red box highlights the alternatively spliced sequence in the top band, which includes a 12-nucleotide insertion predominantly observed in SF3B1 K700E mutant MDS patients. The bottom band sequence is displayed below, showing the canonical exonic sequence. f , Western blot of K562 cells with SF3B1 mutation, TGFBR1 knockout (KO), or TGFBR1 KO with addback of TGFBR1 cDNA encoding the long or short isoform. g, Western blot of cytoplasmic, membrane, and soluble nuclear fractions of K562 cells with TGFBR1 KO alone or with overexpression of TGFBR1 cDNA encoding the long or short isoform.

    Journal: bioRxiv

    Article Title: Ecological determinants of disease and immunity in myelodysplastic syndromes

    doi: 10.64898/2026.05.05.720208

    Figure Lengend Snippet: (a) Sashimi plots of bulk RNA-sequencing data of an aberrant 3’ splice site usage in TGFBR1, MAP3K7 and SMURF2 mRNA in SF3B1 mutant acute myeloid leukemia (AML) (top; n=76 patients), SF3B1 wild-type (WT) AML (middle; n=739 patients), and normal bone marrow (bottom; n=26 patients). Red lines indicate SF3B1 mutant-specific junctions while black lines represent junction spanning reads in wild-type cells. The number of reads is listed, and the frequency of reads is in parentheses. b , Crystal structure of the short-isoform of TGFBR1 (grey) overlaid with that of the alpha-fold predicted model of SF3B1 mutant induced long-isoform (green). c, RT-PCR analysis of aberrant 3’ splice events in TGFBR1, MAP3K7, and SMURF2 in human isogenic K562 cells with knockin of SF3B1 K700E mutation. d , RT-PCR analysis of endogenous TGFBR1 , MAP3K7, and SMURF2 splicing in primary samples in healthy bone marrow control patients (n=5), patients with SF3B1 K700E mutant MDS (n=5) and non-splicing factor mutant patients with MDS (n=5). e , Sanger sequencing electropherogram of the top and bottom PCR products from gel-purified TGFBR1 RT-PCRs from MDS SF3B1 mutant patients shown in ( c ). The red box highlights the alternatively spliced sequence in the top band, which includes a 12-nucleotide insertion predominantly observed in SF3B1 K700E mutant MDS patients. The bottom band sequence is displayed below, showing the canonical exonic sequence. f , Western blot of K562 cells with SF3B1 mutation, TGFBR1 knockout (KO), or TGFBR1 KO with addback of TGFBR1 cDNA encoding the long or short isoform. g, Western blot of cytoplasmic, membrane, and soluble nuclear fractions of K562 cells with TGFBR1 KO alone or with overexpression of TGFBR1 cDNA encoding the long or short isoform.

    Article Snippet: The K562 human myeloid leukemia cell line was purchased from American Type Culture Collection (ATCC; #CCL-243).

    Techniques: RNA Sequencing, Mutagenesis, Reverse Transcription Polymerase Chain Reaction, Knock-In, Control, Sequencing, Purification, Western Blot, Knock-Out, Membrane, Over Expression

    The Effect of lovastatin on the activity, cell cycle, and apoptosis in AML cell lines K562 and THP-1 in vitro. ( A and B ) Effects of lovastatin and 4-PBA at different concentrations on cell activities of THP-1 and K562; ( C ) Effects of lovastatin and 4-PBA on cell cycles of THP-1 and K562; ( D ) Effects of lovastatin and 4-PBA on cell apoptosis of THP-1 and K562. AML, acute myeloid leukemia. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 hours; **** p <0.0001.

    Journal: International Journal of General Medicine

    Article Title: Lovastatin Targets LIPA to Induce ER Stress-Mediated Apoptosis in Acute Myeloid Leukemia: A Multi-Omics Study

    doi: 10.2147/IJGM.S591023

    Figure Lengend Snippet: The Effect of lovastatin on the activity, cell cycle, and apoptosis in AML cell lines K562 and THP-1 in vitro. ( A and B ) Effects of lovastatin and 4-PBA at different concentrations on cell activities of THP-1 and K562; ( C ) Effects of lovastatin and 4-PBA on cell cycles of THP-1 and K562; ( D ) Effects of lovastatin and 4-PBA on cell apoptosis of THP-1 and K562. AML, acute myeloid leukemia. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 hours; **** p <0.0001.

    Article Snippet: The human leukemia cell lines K562 (ATCC ® CCL-243TM) and THP-1 (ATCC ® TIB-202TM) were commercially obtained from Sangon Biotech (Shanghai, China).

    Techniques: Activity Assay, In Vitro

    The mRNA expression levels of LIPA, ATF6, eIF2α, XBP1, IRE1A, DDIT3, HSP90AA1, and PERK. ( A-H ) The ER biomarkers expression in K562 cells ( I-P ). The ER biomarkers expression in THP-1 cells. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 h; **** p <0.0001.

    Journal: International Journal of General Medicine

    Article Title: Lovastatin Targets LIPA to Induce ER Stress-Mediated Apoptosis in Acute Myeloid Leukemia: A Multi-Omics Study

    doi: 10.2147/IJGM.S591023

    Figure Lengend Snippet: The mRNA expression levels of LIPA, ATF6, eIF2α, XBP1, IRE1A, DDIT3, HSP90AA1, and PERK. ( A-H ) The ER biomarkers expression in K562 cells ( I-P ). The ER biomarkers expression in THP-1 cells. Cells were treated with lovastatin (100 μM) or 4-PBA (5 μM) for 24 h; **** p <0.0001.

    Article Snippet: The human leukemia cell lines K562 (ATCC ® CCL-243TM) and THP-1 (ATCC ® TIB-202TM) were commercially obtained from Sangon Biotech (Shanghai, China).

    Techniques: Expressing